Soluble interleukin-2 receptor as an indicator of immunological disturbance found in silicosis patients

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 1, 2009, Pages 53-62

  Hayashi, H ^a   Maeda, M ^a   Murakami, S ^a   Kumagai, N ^a   Chen, Y ^a   Hatayama, T ^a   Katoh, M ^a   Miyahara, N ^a   Yamamoto, S ^a   Yoshida, Y ^a   Nishimura, Y ^a   Kusaka, M ^b   Fujimoto, W ^a   Otsuki, Takemi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Kusaka Hospital   (Japan)

Author keywords

Autoimmune diseases; SIL 2R; Silicosis; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; CENTROMERE ANTIBODY; COMPLEMENT; FAS ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; SCL 70 ANTIBODY; SOLUBLE INTERLEUKIN 2 RECEPTOR;

ADULT; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; MALE; PRIORITY JOURNAL; SILICOSIS; SYSTEMIC SCLEROSIS; VITAL CAPACITY;

EID: 62649093102     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200107     Document Type: Article

References (31)

1. Rushton L. Chronic obstructive pulmonary disease and occupational exposure to silica. Rev Environ Health 2007; 22:255-72.
2. Kroesen S, Itin PH, Hasler P. Arthritis and interstitial granulomatous dermatitis (Ackerman syndrome) with pulmonary silicosis. Semin Arthritis Rheum 2003; 32:334-40.
3. Shanklin DR, Smalley DL. The immunopathology of siliconosis. History, clinical presentation, and relation to silicosis and the chemistry of silicon and silicone. Immunol Res 1998; 18:125-73.
4. Caplan SN, Berkman EM. Immunosuppressive therapy of idiopathic thrombocytopenic purpura. Med Clin North Am 1976; 60:971-86.
5. Haustein UF, Anderegg U. Silica induced scleroderma - clinical and experimental aspects. J Rheumatol 1998; 25:1917-26.
6. Cooper GS, Miller FW, Germolec DR. Occupational exposures and autoimmune diseases. Int Immunopharmacol 2002; 2:303-13.
7. Hölmich LR, Lipworse L, McLaughlin JK, Friis S. Breast implant rapture and connective tissue disease: a review of the literature. Plast Reconstr Surg 2007; 120:62S-9S.
8. Otsuki T, Maeda M, Murakami S, et al. Immunological effects of silica and asbestos. Cell Mol Immunol 2007; 4:261-8.
9. Otsuki T, Miura Y, Nishimura Y, et al. Alterations of Fas and Fas-related molecules in patients with silicosis. Exp Biol Med (Maywood) 2006; 231:522-33.
10. Otsuki T, Miura Y, Maeda M, Hayashi H, Dong M, Nishimura Y. Keynote lecture in the 13th Japanese Society of Immunotoxicology (JSIT 2006) -Pathophysiological Development and Immunotoxicology: what we have found from the researches related to the silica and silicate such as asbestos. Environ Health Prev Med 2007; 12:153-64.
11. Nagata S. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model. J Hum Genet 1998; 43:2-8.
12. Tomokuni A, Aikoh T, Matsuki T, et al. Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Clin Exp Immunol 1997; 110:303-9.
13. Tomokuni A, Otsuki T, Isozaki Y, Kita S, Ueki H, Kusaka M, Kishimoto T, Ueki A. Serum levels of soluble Fas ligand in patients with silicosis. Clin Exp Immunol 1999; 118:441-4.
14. Otsuki T, Sakaguchi H, Tomokuni A, et al. Soluble Fas mRNA is dominantly expressed in cases with silicosis. Immunology 1998; 94:258-62.
15. Otsuki T, Tomokuni A, Sakaguchi H, et al. Over- expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients. Clin Exp Immunol 2000; 119: 323-7.
16. Otsuki T, Sakaguchi H, Tomokuni A, et al. Detection of alternatively spliced variant messages of Fas gene and mutational screening of Fas and Fas ligand coding regions in peripheral blood mononuclear cells derived from silicosis patients. Immunol Lett 2000; 72:137-43.
17. Solomon A, Rees D, Felix M, Venter E. Silicosis and tuberculosis: a proposed radiographic classification of tuberculosis to accompany the ILO international classification of radiographs of pneumoconioses. Int J Occup Environ Health 2000; 6:215-9.
18. Otsuki T, Ichihara K, Tomokuni A, et al. Evaluation of cases with silicosis using the parameters related to Fas-mediated apoptosis. Int J Mol Med 1999; 4:407-11.
19. Obara T, Vodian MA, Kung PC. Clinical significance of soluble interleukin 2 receptor for monitoring the diseases associated with activated lymphocytes and viral infections. J Clin Lab Anal 1992; 6:423-36.
20. LinksPui CH, Ip SH, Kung P, Dodge RK, Berard CW, Crist WM, Murphy SB. High serum interleukin- 2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma. Blood 1987; 70:624-8.
21. Yasuda N, Lai PK, Ip SH, Kung PC, Hinuma Y, Matsuoka M, Hattori T, Takatsuki K, Purtilo DT. Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood 1988; 71:1021-6.
22. Wood NC, Symons JA, Duff GW. Serum interleukin- 2-receptor in rheumatoid arthritis: a prognostic indicator of disease activity? J Autoimmun 1988; 1: 353-61.
23. Airǒ P, Braga S, Prati E, Brugnoni D, Bettinzioli M, Gorla R, Cattaneo, R. Evaluation of serum levels of soluble interleukin-2 receptor as an indicator of disease activity in systemic lupus erythematosus. Clin Rheumatol 1992; 11:97-100.
24. Wu P, Miura Y, Hyodoh F, et al. Reduced function of CD4+25+ regulatory T cell fraction in silicosis patients. Int J Immunopathol Pharmacol 2006; 19: 357-68.
25. Witkowska AM. On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediators Inflamm 2005; 2005:121-30.
26. Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska K Jr. Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations. Arthritis Rheum 1990; 33: 375-80.
27. Kantor TV, Friberg D, Medsger TA Jr, Buckingham RB, Whiteside TL. Cytokine production and serum levels in systemic sclerosis. Clin Immunol Immunopathol 1992; 65:278-85.
28. Bruns M, Herrmann K, Haustein UF. Immunologic parameters in systemic sclerosis. Int J Dermatol 1994; 33:25-32.
29. Lee YJ, Shin KC, Kang SW, Lee EB, Kim HA, Song YW. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis. Clin Exp Rheumatol 2001; 19:69-74.
30. La Montagna G, D'Angelo S, Valentini G. Cross- sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease. J Rheumatol 2003; 30:2147-51.
31. Martinez JA, Nishimura C, Guatura SB, Sato E, King TE Jr. Elevation of soluble interleukin-2 receptor levels in the bronchoalveolar lavage from patients with systemic sclerosis. Rheumatol Int 2001; 21:122-6.